Pharmacological blockade of kininase 1 (CPM) for 1-week provided similar beneficial effects to a corresponding treatment with a B1R antagonist in insulin resistance and peripheral inflammation induced by high glucose feeding. The gene discussed is CPN1; the disease is Insulin resistance.